Snapshot

The Abridged Review pathway has been developed by the National Directorate of Pharmacy in the Mozambique Ministry of Health of Mozambique.

This pathway can be used where For WHO CRP, SRA-approved, and ZaZiBoNa-recommended products. .

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

When relevant, the agency relies on prior decisions from Brazil Canada China EU-EMA Japan Mexico Saudi Arabia Singapore South Korea Switzerland Taiwan (Chinese Taipei) Turkey United Kingdom United States WHO Zazibona

270